Rosetta Genomics (ROSG), Sheba Medical Center Enter MicroRNA-Based BiomarkerResearch Collaboration
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Rosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to Leading Immuno-Oncology Drug Nivolumab in Lung Cancer Patients
November 21, 2016 8:00 AM ESTPHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into a research agreement with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict response to Nivolumab, an immunotherapy drug marketed as Opdivo®, which is approved for the treatment of lung cancer patients.
The prospective study, Circulating microRNA Biomarkers for Lung Cancer Patient Response to the Drug Nivolumab when Administered as Second Line, will be led by Jair Bar, M.D., Deputy... More